- Home
- ILPT vs TLSA Comparison
ILPT vs TLSA Comparison
Compare ILPT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- TLSA
- Stock Information
- Founded
- ILPT 2017
- TLSA 2013
- Country
- ILPT United States
- TLSA United Kingdom
- Employees
- ILPT N/A
- TLSA N/A
- Industry
- ILPT Real Estate Investment Trusts
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- TLSA Health Care
- Exchange
- ILPT Nasdaq
- TLSA Nasdaq
- Market Cap
- ILPT 217.6M
- TLSA 187.0M
- IPO Year
- ILPT 2018
- TLSA 2000
- Fundamental
- Price
- ILPT $5.99
- TLSA $1.48
- Analyst Decision
- ILPT Buy
- TLSA
- Analyst Count
- ILPT 2
- TLSA 0
- Target Price
- ILPT $10.00
- TLSA N/A
- AVG Volume (30 Days)
- ILPT 745.4K
- TLSA 242.1K
- Earning Date
- ILPT 07-29-2025
- TLSA 07-22-2025
- Dividend Yield
- ILPT 0.67%
- TLSA N/A
- EPS Growth
- ILPT N/A
- TLSA N/A
- EPS
- ILPT N/A
- TLSA N/A
- Revenue
- ILPT $441,992,000.00
- TLSA N/A
- Revenue This Year
- ILPT $3.09
- TLSA N/A
- Revenue Next Year
- ILPT $1.79
- TLSA N/A
- P/E Ratio
- ILPT N/A
- TLSA N/A
- Revenue Growth
- ILPT 0.61
- TLSA N/A
- 52 Week Low
- ILPT $2.45
- TLSA $0.63
- 52 Week High
- ILPT $6.00
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- ILPT 84.50
- TLSA 47.20
- Support Level
- ILPT $4.50
- TLSA $1.43
- Resistance Level
- ILPT $4.77
- TLSA $1.81
- Average True Range (ATR)
- ILPT 0.23
- TLSA 0.09
- MACD
- ILPT 0.09
- TLSA -0.02
- Stochastic Oscillator
- ILPT 98.73
- TLSA 13.16
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.